Alternative 5‐Azacitidine 5‐Day 100 mg/m 2 Dosage Shows Non‐Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Treatment

Documenti analoghi

• Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts
  di: Shan Meng, et al.
  Pubblicazione: (2026)
• Intersecting Anemias: PARP Inhibitor‐Induced Toxicity and Autoimmune Hemolysis—A Case Report
  di: Julien Dereme, et al.
  Pubblicazione: (2025)
• Real‐World Healthcare Resource Utilisation in Patients With Higher‐Risk Myelodysplastic Syndrome During Azacitidine Treatment: A Population‐Based Cohort Study
  di: Simone Juline Brommann, et al.
  Pubblicazione: (2025)
• Targeted management of coexistent severe thrombophilias—A case report of a successful pregnancy despite paroxysmal nocturnal hemoglobinuria and hereditary protein C deficiency
  di: Julien Dereme, et al.
  Pubblicazione: (2024)
• Uncommon Evolution From Acute Myeloid Leukaemia to JAK2 ‐Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From TET2 / SRSF2 ‐Mutated Haematopoietic Progenitors
  di: Mark Anthony Turingan, et al.
  Pubblicazione: (2025)